Business
Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and EDP-323, its L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18 both virtually and at the Bella Center Copenhagen in Copenhagen, Denmark.\n\n\nPoster Presentations:\nDate: Monday, April 17, 2023\nTime: 12:00 – 1:30 p.m. Central European Summer Time (CEST)\nSession Title: 12e. Drug development and treatment modalities (including in vitro, animal, clinical trials, resistance)\nPoster Number: P2633\nTitle: “EDP-235, a Potent, Once-Daily, Oral Antiviral, Demonstrates Potential for Treatment and Prevention of Long COVID”\nPresenter: Yang Li, Ph.D.\n\n\nDate: Monday, April 17, 2023\nTime: 12:00 – 1:30 p.m. CEST\nSession Title: 1c. Influenza and respiratory viruses (including diagnostics and epidemiology, antiviral drugs, vaccines, treatment and susceptibility/resistance)\nPoster Number: P2844\nTitle: “Pharmacokinetics of EDP-323, a Potent, Once-Daily, Oral Antiviral Treatment for Respiratory Syncytial Virus”\nPresenter: Lisha Xu\n\n\nPosters will be available to view on the conference platform during the conference. Further information about ECCMID 2023 can be found here.\n\n\nAbout Enanta Pharmaceuticals, Inc.\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).\n\n\nEnanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading tre...